Exciva Raises $59M Series B to Fund Phase 2 Trial of Deraphan for Alzheimer’s Agitation
Heidelberg-based Exciva GmbH raised €51 million (US$59.9 million) in a Series B financing round on January 20, 2026.
Funding co-led by EQT Life Sciences, Gimv, with participation from Andera Partners, LBBW, Fountain Healthcare Partners, LifeArc Ventures, Carma Fund, and Modi VC.
Proceeds will primarily fund a Phase 2 clinical trial of lead candidate Deraphan, a combination of two clinically validated compounds including one new chemical entity, for treating agitation in Alzheimer's disease patients.
The international Phase 2 trial will be conducted in Europe, UK, US, and Canada.
Deraphan completed Phase 1 with encouraging safety and tolerability; agitation affects up to 90% of severe Alzheimer's patients, representing a major unmet need.
Exciva founded in 2016; previous funding included €9M Series A in 2021, bringing total raised to approximately €60M in equity.